SCM
OKUR

Stonepine Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Stonepine Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$549K Buy
+132,578
New +$409K 0.22% 55

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Stonepine Capital Management's OKUR Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in OnKure Therapeutics (OKUR) in Q1 2026: 132,578 shares worth $549K. The stake represents 0.22% of the portfolio and ranks #55 among its holdings.

51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Stonepine Capital Management held 132,578 shares of OnKure Therapeutics worth $549K as of Q1 2026.
  • OnKure Therapeutics was a new Stonepine Capital Management position in Q1 2026.
  • OnKure Therapeutics made up 0.22% of Stonepine Capital Management's portfolio in Q1 2026, its #55 holding.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.